BusinessThe company is a global integrated biopharmaceutical company engaged in the discovery, development and commercialization of first-of-its-kind and best-in-class therapies to address the global unmet medical needs of hematological malignancies.

Introduction

Ascentage Pharmaceutical Group is a holding company mainly engaged in the discovery, research and development and commercialization of drugs for the treatment of hematological malignancies. The company's main business is the development and sale of new small-scale therapies for cancer, hepatitis B and aging-related diseases. The company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The company's products are primarily used to treat major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome and multiple myeloma. The company mainly operates in the domestic market.